Texas § 490.051 PATIENT ELIGIBILITY.

Texas Statutes

§ 490.051 — PATIENT ELIGIBILITY.

Texas § 490.051

Code HSHealth and Safety Code

This text of Texas § 490.051 (PATIENT ELIGIBILITY.) is published on Counsel Stack Legal Research, covering Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Tex. Health and Safety Code Code Ann. § 490.051 (2026).

Text

Sec. 490.051. PATIENT ELIGIBILITY. A patient is eligible to access and use an investigational drug, biological product, or device under this chapter if:

(1)the patient has a severe chronic disease the commissioner designates under Section 490.002 that the patient's treating physician confirms in writing;

(2)the use of the investigational drug, biological product, or device is consistent with this chapter and rules adopted under this chapter; and

(3)the patient's physician:

(A)in consultation with the patient, considers all other treatment options the United States Food and Drug Administration has currently approved and determines those treatment options are unavailable or unlikely to provide relief for the significant impairment or severe pain associated with the patient's severe chron

Free access — add to your briefcase to read the full text and ask questions with AI

Sec. 490.051. PATIENT ELIGIBILITY. A patient is eligible to access and use an investigational drug, biological product, or device under this chapter if:
(1) the patient has a severe chronic disease the commissioner designates under Section 490.002 that the patient's treating physician confirms in writing;
(2) the use of the investigational drug, biological product, or device is consistent with this chapter and rules adopted under this chapter; and
(3) the patient's physician:
(A) in consultation with the patient, considers all other treatment options the United States Food and Drug Administration has currently approved and determines those treatment options are unavailable or unlikely to provide relief for the significant impairment or severe pain associated with the patient's severe chronic disease; and
(B) recommends or prescribes in writing the patient's use of a specific class of investigational drug, biological product, or device.